What Is Boston Doing for the War on Cancer? Find Out at Xconomy Forum on October 20
Summary
We are thrilled to announce our next big public event, “Boston’s War on Cancer.” It will be held on the afternoon of October 20 at Millennium: The Takeda Oncology Company in Cambridge, MA.Millennium CEO Deborah Dunsire will kick things off with her view of the state of the art in cancer drugs in a keynote talk.The group includes Doug Fambrough of Dicerna Therapeutics from the field of RNA interference drugs; Alexis Borisy of Foundation Medicine and Third Rock Ventures on discovery of promising new cancer targets; Mark Goldsmith of Constellation Pharmaceuticals on epigenetics; and Dave Okrongly of Quanterix on new diagnostics precise enough to spot early signs of cancer in a drop of blood.In between, we’ll hear from a distinguished panel of people who have devoted their careers to thinking about how to take promising new cancer drugs all the way through the FDA approval process and into the marketplace.Xconomy’s own life sciences columnist, Sylvia Pagan Westphal, will moderate this conversation about all the opportunities and challenges facing these companies as they pursue new cancer treatments.